EUVIMEDEUVIMED entdecken
Open Access

Inhibition of Acetylation Activity of p300/ CBP Ameliorates Hepatic Steatosis Through Downregulation of ACSL4

Ling-Yan Cai iD, Ya-Ping Guan, Jin-Han Hu, Chun-Yan Sun, Chen-Hong Ding, Xin Zhang iD, Xin Zeng iD, Wei-Fen Xie iD

Liver International · 2026

DOI: 10.1111/liv.70846 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2026. Verfasst von Ling-Yan Cai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Coenzyme A Ligases, p300-CBP Transcription Factors, Fatty Liver, E1A-Associated p300 Protein. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, New Quality Clinical Specialty Program of High-End Medical Disciplinary Construction in Shanghai Pudong New Area.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disorder, with few optimal pharmacotherapies. Ongoing studies are providing evidence that histone acetylation contributes to the progression of MASLD. This study investigated the alterations of specific histone acetylation sites in MASLD tissues and the effects of B029‐2, a small‐molecule inhibitor targeting p300/CBP acetylation activity, in mouse models of progressive fatty liver disease.

Methods

The acetylation of H3K27/H3K18/H3K9 was assessed in liver samples from MASLD patients and mice. The effect of the B029‐2 in MASLD was assessed in MASLD models. A ChIP assay was conducted to investigate the epigenetic regulatory mechanism of ACSL4. Hepatic‐specific Acsl4‐knockout and overexpression mice were generated to validate the role of ACSL4 in MASLD.

Results

We observed a significant increase in p300 HAT activity, p300/CBP‐induced H3K18ac and H3K27ac levels in MASLD and B029‐2 markedly reduced hepatic steatosis in vitro and in vivo. Transcriptome analysis revealed that B029‐2 inhibited the expression of genes in the triglyceride biosynthetic process and long‐chain fatty‐acyl‐CoA biosynthetic process. ChIP assay showed that H3K18ac, H3K27ac and p300 bind to the promoter region of ACSL4 , and their binding is reduced by B029‐2 treatment. AAV‐mediated hepatic‐specific overexpression of Acsl4 attenuated the effect of B029‐2 on MASLD in mice, while hepatic‐specific Acsl4‐deficient in mice blocked the effect of B029‐2. Conclusions p300/CBP‐mediated H3K18ac and H3K27ac regulate ACSL4‐dependent lipid biosynthesis in MASLD and might be a potential therapeutic target for the treatment of MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coenzyme A Ligasesp300-CBP Transcription FactorsFatty LiverE1A-Associated p300 ProteinAnimalsAcetylationDown-RegulationHumansMiceDisease Models, AnimalHistonesMice, KnockoutMaleLiverMice, Inbred C57BLLong-Chain-Fatty-Acid-CoA LigaseBenzoatesNitrobenzenesPyrazolones

Stichwörter der Autor:innen

ACSL4MASLDhistone acetylationinhibitorlipid metabolismp300/CBP

Substanzen

Coenzyme A Ligasesp300-CBP Transcription FactorsAcsl4 protein, mouseHistonesE1A-Associated p300 ProteinLong-Chain-Fatty-Acid-CoA Ligase4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acidBenzoatesNitrobenzenesPyrazolones

Autor:innen und Institutionen

  • Department of Gastroenterology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
  • Department of Gastroenterology, Changzheng Hospital, Naval Medical University, Shanghai, China.

ORCID-Profile: Ling-Yan Cai, Xin Zhang, Xin Zeng, Wei-Fen Xie

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • New Quality Clinical Specialty Program of High-End Medical Disciplinary Construction in Shanghai Pudong New Area

Zitieren

APA

Cai, L. Y., Guan, Y. P., Hu, J. H., Sun, C. Y., Ding, C. H., Zhang, X., Zeng, X., & Xie, W. F. (2026). Inhibition of Acetylation Activity of p300/ CBP Ameliorates Hepatic Steatosis Through Downregulation of ACSL4. Liver International. https://doi.org/10.1111/liv.70846

Vancouver

Cai LY, Guan YP, Hu JH, Sun CY, Ding CH, Zhang X, et al. Inhibition of Acetylation Activity of p300/ CBP Ameliorates Hepatic Steatosis Through Downregulation of ACSL4. Liver International. 2026. doi:10.1111/liv.70846

BibTeX
@article{Cai2026,
  author = {Cai, Ling-Yan and Guan, Ya-Ping and Hu, Jin-Han and Sun, Chun-Yan and Ding, Chen-Hong and Zhang, Xin and Zeng, Xin and Xie, Wei-Fen},
  title = {Inhibition of Acetylation Activity of p300/ CBP Ameliorates Hepatic Steatosis Through Downregulation of ACSL4},
  journal = {Liver International},
  year = {2026},
  doi = {10.1111/liv.70846}
}
Kostenlos starten →